Showing 1231-1240 of 1371 results for "".
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s
- Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://modernaesthetics.com/news/galdermas-aspire-rewards-program-hits-the-million-member-mark/2472003/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- ARTAS iX: Real-World Evaluation Study Shows Benefithttps://modernaesthetics.com/news/artas-ix-real-world-evaluation-study-shows-benefit/2472009/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study of The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implan
- Galderma Announces the Start of Six New Aesthetic Studieshttps://modernaesthetics.com/news/galderma-announces-the-start-of-six-new-aesthetic-studies/2472014/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- Introducing Juvéderm It, Allergan's Newest Ad Campaignhttps://modernaesthetics.com/news/introducing-juvderm-it-allergans-newest-ad-campaign/2472020/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- RealSelf: One in Three U.S. Adults are Considering Nips/Tuckshttps://modernaesthetics.com/news/realself-one-in-three-us-adults-are-considering-nipstucks/2472025/One in three adults (37 percent) in the U.S. are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the
- New Cutera Survey Results Help Define Body Contouring Markethttps://modernaesthetics.com/news/new-cutera-survey-helps-define-body-contouring-market/2472026/One third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results we
- ASPS Members Identify Key Plastic Surgery Trendshttps://modernaesthetics.com/news/asps-members-identify-key-plastic-surgery-trends/2472027/Breast augmentation, tummy tucks and liposuction will be the three most popular plastic surgery procedures in 2019, plastic surgeons predict. With regard to minimally invasive procedures, Botox still leads the way as the most anticipated request, followed by fillers, chemical peels, laser
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin